Pure Biologics Spólka Akcyjna (PUR.WA)

PLN 15.22

(-8.86%)

Market Cap (In PLN)

59.39 Million

Revenue (In PLN)

95 Thousand

Net Income (In PLN)

-35.69 Million

Avg. Volume

203.27 Thousand

Currency
PLN
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.21-33.2
PE
-
EPS
-
Beta Value
1.413
ISIN
PLPRBLG00010
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Filip Jelen M.B.A., Ph.D.
Employee Count
-
Website
https://www.purebiologics.com
Ipo Date
2018-12-01
Details
Pure Biologics Spólka Akcyjna, a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis. Pure Biologics Spólka Akcyjna was founded in 2010 and is headquartered in Wroclaw, Poland.